Phase 2 trial with Avastin and Doxorubicin postoperatively for patients with anaplastic thyroid carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-001783-75-SE

Enrollment

Registered

2008-01-11

Start date

2008-03-31

Completion date

Unknown

Last updated

2015-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients that suffer from anaplastic thyroid cancer and have completed our "standard" initial therapy with radiotherapy and chemotherapy, and has been macroscopical radically resected after completion of initial therapy.

Interventions

Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Concentrate for solution for infusion Other descriptive name: BEVACIZUMABUM Trade Name: doxorubicin Product Name: Adriamycin Pharmaceuti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Verified anaplastic thyroid cancer. • Completion of standard initial therapy with radiotherapy and chemotherapy • Surgically resected with macroscopic radicality • Performance Status ECOG 0-2. If lung metastasis ECOG 0-1 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Performance Status ECOG 3-4. If lung metastasis ECOG 2-4 • Macroscopic evident non-radical surgery.

Design outcomes

Primary

Measure	Time frame
Main Objective: Overall survival Response rate (recist);Secondary Objective: Response rate (FDG-PET) Progression free survival Local control;Primary end point(s): OS Respons rate (recist)	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026